NCT01105533

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.

Conditions

• Neoplasm

Interventions

Type	Name	Description
DRUG	PF-00337210	0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
DRUG	PF-00337210	1mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	2mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	4mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	6mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	9mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	8mg Capsule Once Daily (Dose Escalation) Continuous
DRUG	PF-00337210	4mg Capsule Twice Daily (Dose Escalation) Continuous
DRUG	PF-00337210	6mg Capsule Twice Daily (Dose Escalation) Continuous
DRUG	PF-00337210	6mg Capsule Twice Daily (Dose Expansion) Continuous

Timeline

• Start date: 2006-05-01
• Primary completion: 2010-10-01
• Completion: 2011-09-01
• First posted: 2010-04-16
• Last updated: 2013-03-19
• Results posted: 2013-03-19

Locations

3 sites across 1 country: United States